Hyperhomocysteinemia and impaired vasomotor function in type 2 diabetes mellitus

European Journal of Clinical Investigation

Volumn 32, Issue 5, 2002, Pages 328-334

  Tan, Kathryn C B ^a,b   Karmin, O ^a   Chow, W S ^a,b   Ai, V H G ^a,b   Siow, Y L ^a   Lam, K S L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Diabetes mellitus; Endothelial dysfunction; Homocysteine

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC ANGIOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK FACTOR; VASCULAR ENDOTHELIUM; VASODILATATION; VASOMOTOR DISORDER;

ADULT; BRACHIAL ARTERY; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; RISK FACTORS; VASODILATION;

EID: 0037003369     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.00990.x     Document Type: Article

References (31)

1. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501.
2. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
3. Mayer EL, Jacobsen DW, Robinson KR. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.
4. Welch GN, Loscalzo J. Homocysteine atherothrombosis. N Engl J Med 1998;338:1042-50.
5. Medina MA, Amores-Sanchez MI. Homocysteine: an emergent cardiovascular risk factor? Eur J Clin Invest 2000;30:754-62.
6. Hofmann MA, Kohl B, Zumbach MS, Borcea V, Bierhaus A, Henkels M et al. Hyperhomocyst (e) inemia and endothelial dysfunction in IDDM. Diabetes Care 1998;21:841-8.
7. Munshi MN, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996;45:133-5.
8. Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in type 2 diabetes. Relationship to macroangiopathy, nephropathy and insulin resistance. Diabetes Care 2000;23:1816-22.
9. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJC, Jakobs C, Bouter LM et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus. A population-based study. Arterioscler Thromb Vasc Biol 1998;18:133-8.
10. Okada E, Oida K, Tada H, Asazuma K, Eguchi K, Tohda G et al. Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 1999;22:484-90.
11. Stehouwer CD, Gall MA, Hougaard P, Jakobs C, Parving HH. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. Kidney Int 1999;55:308-14.
12. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst (e) inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-21.
13. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY et al. Hyperhomocyst (e) inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997;96:2542-4.
14. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst (e) inaemia: restoration by folic acid. Clin Sci 1999;96:235-9.
15. Chambers JC, Ueland PM, Obeid OA, Wrigley J, Refsum H, Kooner JS. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000;102:2479-83.
16. Becker A, Van Hinsbergh VW, Kostense PJ, Jager A, Dekker JM, Nijpels G et al. Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule 1, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects - The Hoorn Study. Eur J Clin Invest 2000;30:763-70.
17. Tan KC, Ai VH, Chow WS, Chau MT, Leong L, Lam KS. Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes. J Clin Endocrinol Metab 1999;84:3212-6.
18. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
19. Bhagat K, Hingorani A, Vallance P. Flow associated or flow mediated dilatation? More than just semantics. Heart 1997;78:7-8.
20. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
21. Upchurch GR, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF et al. Homocyst (e) ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012-7.
22. Chambers JC, Obeid OA, Kooner JS. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb Vasc Biol 1999;19:2922-7.
23. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 1999;99:1156-60.
24. Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997;350 (Suppl. 1):19-13.
25. Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci 1996;91:567-73.
26. Wang G, Siow YL. Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C. Biochem J 2000;352:817-26.
27. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994;91:6369-73.
28. Chen C, Halkos ME, Surowiec SM, Conklin BS, Lin PH, Lumsden AB. Effects of homocysteine on smooth muscle cell proliferation in both cell culture and artery perfusion culture models. J Surg Res 2000;88:26-33.
29. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:2074-81.
30. Mujumdar VS, Hayden MR, Tyagi SC. Homocyst (e) ine induces calcium second messenger in vascular smooth muscle cells. J Cell Physiol 2000;183:28-36.
31. van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost 2000;26:281-9.